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Abstract Intestinal metabolism can limit oral bioavail-
ability of drugs and increase the risk of drug interactions. It is
therefore important to be able to predict and quantify it in drug
discovery and early development. In recent years, a plethora
of models—in vivo, in situ and in vitro—have been discussed
in the literature. The primary objective of this review is to
summarize the current knowledge in the quantitative predic-
tion of gut-wall metabolism. As well as discussing the suc-
cesses of current models for intestinal metabolism, the
challenges in the establishment of good preclinical models are
highlighted, including species differences in the isoforms;
regional abundances and activities of drug metabolizing
enzymes; the interplay of enzyme-transporter proteins; and
lack of knowledge on enzyme abundances and availability of
empirical scaling factors. Due to its broad specificity and high
abundance in the intestine, CYP3A is the enzyme that is
frequently implicated in human gut metabolism and is
therefore the major focus of this review. A strategy to assess
the impact of gut wall metabolism on oral bioavailability
during drug discovery and early development phases is pre-
sented. Current gaps in the mechanistic understanding and the
prediction of gut metabolism are highlighted, with sugges-
tions on how they can be overcome in the future.
Key Points
A summary of current knowledge for the prediction
of intestinal metabolism using in vivo, in situ,
in vitro and mathematical models is provided.
A strategy for the prediction of intestinal extraction
that can be applied in drug discovery and early
development is outlined.
Gaps in current knowledge and technology that
hamper the prediction of intestinal metabolism have
been identified and a future direction proposed.
1 Introduction
Oral dosing is the preferred route of administration as it is
cheap, convenient and safe for patients [1, 2]. However,
oral drug bioavailability is often limited by first-pass
extraction in the gut and liver requiring higher doses
compared with intravenous administration. Poor oral
bioavailability has led to the failure of many drugs. As
such, pharmaceutical companies aim to minimize hepatic
and intestinal metabolism through drug design during lead
optimization (LO). Oral bioavailability (F) is defined as:
F ¼ FaFGFH
where Fa is the fraction of orally administered drug that is
absorbed into the enterocytes, FG is the fraction of drug
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escaping first-pass metabolism in the enterocytes, and FH is
the fraction of drug escaping first-pass hepatic metabolism
and biliary secretion. Absolute oral bioavailability
(Fa 9 FG 9 FH) is determined by comparing the drug
exposure (area under the plasma concentration–time pro-
file) following oral administration with that after intra-
venous administration, assuming that first-pass metabolism
from organs other than liver and gut can be neglected.
Intestinal metabolism can occur in the gut lumen as well
as in enterocytes. In the gut lumen, microflora-mediated
reduction [3] and hydrolysis [4–6] can be important but are
often overlooked. Among the drug metabolizing enzymes
(DMEs) expressed in human enterocytes [7], cytochrome
P450 (CYP450), uridine diphospho-glucuronosyltrans-
ferases (UGTs) and sulphotransferases (SULTs) are the
most important (Table 1). CYP3A is localized predomi-
nantly in functionally mature enterocytes at the villous tips,
which result from migration of immature enterocytes in the
crypts, a process that takes approximately 2–6 days [7].
Recently, meta-analysis has indicated that turnover of
mature enterocytes in preclinical species and humans takes
between 2.4 and 3.5 days [8]. The total mass of CYP3A in
the entire small intestine based on homogenates from iso-
lated enterocytes has been estimated to be less than 1 % of
the liver [9, 10]. However, the intestine contributes sig-
nificantly, or even equal, to hepatic CYP3A in the overall
first-pass metabolism of several drugs (e.g. cyclosporine,
midazolam and verapamil) [11–13]. Extensive presystemic
intestinal metabolism is probably due to anterior position-
ing of the intestine with respect to the liver; the high
luminal drug concentration and the long intestinal transit
times that provide an increased opportunity for substrate–
enzyme interaction, especially given the potential syner-
gistic interplay of CYP3A and P-glycoprotein (P-gp) on
dual substrates [14–16]. Additionally, unlike hepatic
metabolism, presystemic metabolism is not limited by
plasma protein binding or blood perfusion rates, but rather
by permeability across enterocytes [17].
Poor oral bioavailability and extensive first-pass meta-
bolism predisposes a patient population to potential
Table 1 Major CYP450
enzymes identified in the human
gut according to published
protein abundance data
Enzyme class Enzyme isoform (% of total) References
CYP P450 CYP3A4 (33–87)
CYP2C9 (4–38) and CYP2C19 (0.5–7)
[9, 266]
Other isoforms:





Contributions (ranges) were calculated as a percentage of the










Eight UGT1A isoforms were evaluated and their mean
contributions were calculated as a percentage of the total







Five SULT isoforms were evaluated and their mean
contributions were calculated as a percentage of the total
amount of immunoquantified SULT (n = 6 donors)
[140, 148]
CYP450 cytochrome P450, UGTs uridine diphospho-glucuronosyltransferases, SULTs sulphotransferases
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toxicity arising from high doses as well as large
interindividual variability [18] in exposures. In addition,
extensive first-pass metabolism increases the risk of drug–
drug interactions (DDIs) [19–23], the magnitude of which
depends on the fraction escaping metabolism of both the
substrate and the inhibitor [24] (if both the substrate and
inhibitor are metabolized by the inhibited enzyme). The
DDI risk arising from first-pass extraction can also be
transporter-mediated [25–28]. These risks highlight the
need for robust, quantitative models for predicting drug
extraction through the gut wall and liver, backed by a
sound understanding of the underlying mechanisms.
After decades of research, hepatic drug metabolism is
well-understood. Only in recent years has there been an
increased effort to understand intestinal first-pass extrac-
tion. Among the factors limiting intestinal availability
(Fa 9 FG), intestinal metabolism can be a major determi-
nant [29] but is poorly understood. This is due to a number
of confounding factors affecting it; namely, drug transit
through the gastrointestinal tract, drug permeability, solu-
bility and intestinal blood flow. Species differences in the
isoforms, regional abundances and activities of DMEs [9,
30, 31] and transporters [32, 33], as well as the interplay of
enzyme-transporter proteins and overlap of substrate and
inhibitor specificity [34], make it difficult to establish good
preclinical models for this process. Knowledge gaps on
enzyme abundances and lack of empirical enzyme activity
scaling factors are the main limitations of in vitro methods
for the evaluation of intestinal metabolism. The large
interindividual variability and inaccurate estimation of
human intestinal extraction, even when intravenous phar-
macokinetic (PK) data are available, pose additional chal-
lenges to the validation of both in vitro and in vivo models
[35, 36]. Due to its broad specificity and high abundance in
the intestine, CYP3A is the enzyme most frequently
implicated in human gut metabolism, and therefore the
most studied. Focusing on CYP-mediated processes, this
review will summarize current knowledge on the advan-
tages and limitations of preclinical models (in vivo, in situ,
in vitro and mathematical) available for quantitative pre-
diction of intestinal availability. This review will also
outline a strategy applicable in drug discovery and early
development, identify gaps in current understanding and
propose future directions for the prediction of human gut-
wall metabolism.
2 Human In Vivo FG
Seminal work from clinical studies with CYP3A drug
substrates such as cyclosporine A [11, 37, 38] and mida-
zolam [12, 39, 40] established the role of gut-wall meta-
bolism in limiting human oral bioavailability. Substantial
intestinal extraction was demonstrated in patients after
sampling portal vein blood following intraduodenal drug
administration during the anhepatic phase of liver trans-
plantations. However, interpretation of this PK data is
challenging given confounding factors attributable to the
use of anaesthetics, surgery and the often poor condition of
patients. These studies, as with in situ regional perfusions
[41, 42], are rarely undertaken in humans for ethical,
technical and cost reasons [21, 43].
Alternative clinical approaches rely on indirect estima-
tion of human FG from intravenous/oral area under the
curve (AUC) data or drug–food interaction data. Compar-
ison of AUCs following intravenous and oral drug
administration is relatively straightforward, although
assumptions often hinder interpretation [44]. For example,
the extent of metabolic extraction in the intestine can be
over-emphasized if (1) notable extrahepatic systemic
clearance is left unaccounted [45]; (2) the blood:plasma
ratio deviates significantly from unity [46]; or (3) first-
order elimination is not conserved at each site of drug
administration [47, 48]. Additionally, calculated FG can be
sensitive and biased according to the average value used
for liver blood flow [49, 50]. When factors limiting oral
absorption (efflux, low Fa) are minimal and transporter-
mediated uptake is negligible [46, 51], the drug–food
interaction method offers an attractive, pragmatic model
for estimating the extent of FG for CYP3A drug substrates.
This is because certain fruit juices offer complete and
exclusive presystemic inhibition of CYP3A in the small
intestine, providing means for FG to be more readily
identifiable and separated from hepatic first-pass elimina-
tion [52–58]. Advantageously, the interaction approach
requires only measurement of oral AUC in the presence
and absence of inhibitor, avoids many of the confounding
factors associated with the intravenous/oral method, and
allows researchers to benefit from the abundance of clinical
data available [46, 51]. Clinical studies helped to delineate
the metabolic component in liver and intestine for drugs
such as alfentanil, cyclosporine, felodipine, midazolam,
nifedipine and tacrolimus [46, 52, 54–56, 59, 60]. Grape-
fruit juice (GFJ) has been the most popular CYP3A inhi-
bitor in food–drug interactions trialled thus far. The extent
of clinical drug interactions with GFJ can be variable,
depending on the GFJ strength and duration of adminis-
tration [51, 61, 62]. Understanding underlying mechanisms
and kinetics should aid study design and control exposure
to inhibitory agents (furanocoumarins) mediating the
interactions [57, 58, 61, 63–65]. In turn, this should address
interstudy reproducibility and erroneous estimation of FG
[21]. Detailed discussion of the advantages, limitations and
underlying assumptions of these in vivo models are elab-
orated elsewhere [21, 46, 51]. Uncoupling FG and Fa
remains a significant challenge to any clinical approach, as
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does factoring out potential contributions from nonhepatic
tissues [43].
3 Regional Differences in Intestinal Metabolism
and Transport in the Human Gut
Compounds that have their maximum absorption in dif-
ferent regions of the gut are likely to have very different
FG, even if they have comparable metabolic liabilities. This
is probably due to regional differences in drug uptake into
enterocytes, efflux and intestinal metabolism arising from
regional variation in the luminal environment (e.g. pH,
composition of intestinal fluids) [66–68] and epithelial
membrane (e.g. surface area, expression of enzymes and
transporters) [67]. Information on regional expression of
enzymes and transporters is important for understanding
the in vivo plasma PK profile and possible DDIs with co-
medications.
It is well known that passive diffusion varies in humans
and preclinical models according to the physicochemical
properties of the drug in question and the region of intes-
tine [69, 70]. Lipophilic compounds have the same or
higher permeability coefficients in the lower bowel com-
pared with the upper small intestine. With hydrophilic
molecules the trend is reversed [69, 70], partly due to
differences in the membrane lipid composition and the
tightness of the tight junctional area [70]. Regional dif-
ferences in drug uptake into the enterocytes can also occur
due to differences in intracellular metabolism along the
gut. Higher rates of intracellular metabolism can cause sink
conditions inside the cells. A concentration gradient
maintained across the membrane favors increased uptake,
as has been suggested for indinavir [71].
Efflux proteins impact gut metabolism by reducing the
intracellular drug concentrations exposed to DMEs in the
enterocytes. At high doses, efflux proteins may become
saturated, allowing a larger proportion of drug to pass the
membrane efficiently. Expression of the main ABC trans-
porters is heterogeneous along the gastrointestinal tract
(Table 2) [72–74]. It is well known that multidrug resis-
tance protein 1 (MDR1) [ABCB1, P-gp] is preferentially
expressed toward the lower parts of the human small
intestine (ileum) [74–76], while multidrug resistance-as-
sociated protein 3 (MRP3) [ABCC3] is expressed at higher
levels than MDR1 along the small and large intestines [74].
In contrast, the efflux protein MRP2 (ABCC2) is expressed
at relatively high levels in the small intestine but at
extremely low levels in the colonic regions [74]. The other
important efflux protein, breast cancer resistance protein
(BCRP) (ABCG2), has higher levels than both MRP2 and
MRP3 in the small intestine, but very low levels in the
colonic regions [77, 78].
The solute carrier (SLC) proteins, including PepT1
(SLC15A), MCT1 (SLC16A), OATPs (OATP2B1; SLC0),
OATs (SLC22A), OCT/OCTN (SLC22A) and the recently
described PMAT (SLC29), may add significantly to uptake
of the drug into enterocytes for many compounds with
lower lipophilicities ([72], and refs. therein). These are also
affected by food constituents as well as genetic polymor-
phisms and disease states [79, 80]. OATP2B1 has been
found to have an unexpected influence on the absorption of
the drug aliskiren [81]. The compound has affinity for
MDR1 as well as CYP3A4, and inhibition of these mech-
anisms was expected to increase its bioavailability. How-
ever, in a study involving 11 healthy volunteers, a
reduction of the absorption of aliskiren was found, when
coadministered with GFJ, due to additional inhibition of
the uptake transporter OATP2B1 by GFJ. Thus, prediction
of drug absorption and DDI in the clinic gets further
complicated for substrates of uptake transporters.
The regional distribution of these SLC proteins in the
intestine, as well as species differences, are largely
unknown. However, PepT1 is reported to be highly dis-
tributed in the proximal intestine of humans and many
animal models [72, 82], and MCT1 is well known to be
highly abundant along the whole gastrointestinal tract. The
abundances of other SLC proteins tend not to be significant
[78, 83, 155]. Further details can be found in the excellent
review by Estudante et al., and references therein [72].
The abundance and catalytic activity of the main human
CYP450 enzymes is generally highest in the proximal
regions (i.e. duodenum and proximal jejunum), declining
towards the lower ileum after a slight increase from the
duodenum to the jejunum (Table 2) ([84–87], and refs.
therein]). Data on regional gene expression and enzymatic
activity are readily available for CYP3A4 and members of
the CYP2C family, but are less well-characterized for other
CYP450s. Paine et al., measured CYP450 protein levels
along the gastrointestinal tract in 31 human donors and found
that after CYP3A4, the most abundant enzyme was CYP2C9,
then CYP2C19 with low levels of CYP2J2 and CYP2D6 [9].
Western blot data indicated that concentrations of CYP3A4
and CYP2C isoforms decreased dramatically towards the
distal small intestine, with CYP2C levels falling faster
compared with CYP3A4 [9, 86]. Information available on
the expression of CYP450s in the human colonic enterocyte
is limited, and is contradictory depending on the technique
used [88–90]. Using messenger RNA (mRNA) and protein
analysis, Bergheim et al., [91] found expression levels of
CYP2C, CYP2E1 and CYP3A5 significantly differed
between different regions of the large intestine, with CYP2C
significantly higher in the ascending colon, and CYP2E1 and
CYP3A5 significantly lower. In contrast, others failed to
detect any significant levels of CYP4502C8–10 and
CYP2E1 protein in colonic tissue [63, 64].
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The most obvious difference between the small intestine
and colonic tissue is the content of CYP3A4 and CYP3A5.
In the small intestine, CYP3A5 is detected only at low
levels [89] and may be absent in some individuals [9],
while in colonic tissues, very low levels of CYP3A4 and
higher relative expression of CYP3A5 were reported. Thus,
CYP3A5 constituted the major CYP3A isoform in this
tissue [88]. The overall lower rate of hydroxylation in the
colonic region compared with the proximal jejunum was
confirmed by van de Kerkhof et al., using a mixture of
Table 2 Regional distribution of important phase I and II enzymes and ABC transporters along the small and large intestine in humans and
common preclinical species






Human CYP3A 3A4 highest expressed of all CYPs,
duodenum\ jejunum[ ileum, colon
3A5 small intestine\ colon (major CYP
in colon)
3A5 in some cases high in proximal
intestine











Dog Cyp3a12/26 Very low levels, no regional difference [159] P-gp, mdr1
(ABCB1)
Apical; highest in jejunum,
low in colon and
duodenum
[159]
Human CYP2B6 Not expressed [10] MRP2 (ABCC2) Apical; proximal[ distal
jejunum[ ileum[colon
[74]
Rat Cyp2b1 Higher or similar expression as for 3A,
duodenum\ jejunum[ ileum, colon
[154] mrp2 (ABCC2) Apical; proximal[ distal
Human CYP2C9/19 Second most abundant, proximal intestine [9] MRP3 (ABCC3) Basolateral; high level
overall, proximal\ distal
[74, 78]
Rat Cyp2c6 Duodenum = jejunum\ ileum\ colon [154] mrp3 (ABCC3)a Basolateral;
proximal\ distal; highly
expressed in the colon
[160]






Rat Cyp1a1 Main CYP in the small intestine bcrp (ABCG2) Highest in mid jejunum [162]
Dog No reports found [90] BCRP (ABCG2) Tenfold higher than MDR1
and proximal  ileum,
colon
[159]
Human UGT Similar activity in both small intestine
and colon
[157]
Rat UGT Proximal small intestine[ distal small
intestine
[159]
Dog UGT High level throughout the intestine and
colon
[90]
Human SULT Similar activity in both small intestine
and colon
[157]
Rat SULT Proximal small intestine[ distal small
intestine
[9]
Dog SULT No reports found
The abundance of the different proteins in the different regions was mainly reported as levels of mRNA, immunoquantification and enzyme
activities
CYP cytochrome P450, UGT uridine diphospho-glucuronosyltransferase, SULT sulphotransferase, P-gp P-glycoprotein, MDR1 multidrug
resistance protein 1, MRP2 multidrug resistance-associated protein 2, MRP3 multidrug resistance-associated protein 3, BCRP breast cancer
resistance protein, mRNA messenger RNA
a Refers to rat and mouse
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CYP450 substrates [CYP3A4/5 substrate midazolam
(CYP3A4/5), followed by CYP2C9 (diclofenac) and
CYP2D6 (bufuralol)] [90].
Regional differences in the abundance of phase II
enzymes in the gut are not well-understood. van de Ker-
khof et al. have reported similar activity for UGT and
SULT enzymes [based on 7-hydroxy-coumarin (7-HC)
conjugation] in both the proximal jejunum and the colon.
They also report that glucuronidation efficiency in the gut
was approximately sixfold higher than sulphation in both
regions [90]. As with all quantitative approaches to mea-
suring transporter and DME protein abundances, compar-
ison of expression levels of different phase I and II
enzymes between regions of the small intestine and colonic
tissue, and between different studies, may be difficult given
the different techniques used for quantification, i.e. protein
quantitation using Western blot or liquid chromatography–
tandem mass spectrometry (LC–MS/MS), as well as
immunohistochemistry, mRNA and enzymatic activity
using selected probes.
4 Combined Action of Drug Metabolizing
Enzymes (DMEs) and Transporters in the Gut
Co-localization of CYP3A and MDR1 in the enterocyte
along the crypt villus axis, overlapping substrate speci-
ficities and poor oral bioavailability of their joint substrates
[15], have lead scientists to suspect an interplay between
ABC transporters and members of the CYP450 enzyme
families in the intestinal membrane affecting intestinal
absorption and metabolism. It may also explain some DDIs
which cannot be rationalized through either protein acting
alone [15, 72].
P-gp is situated in the apical membrane of the enterocyte
and efflux substrates from inside the cell towards the
intestinal lumen. The CYP3A enzymes are located within
the endoplasmic reticulum. It is therefore suggested that
P-gp may regulate the intracellular concentration of dual
substrates of P-gp and CYP3A. One might speculate that
increasing P-gp levels in the proximal to distal direction
serves to recycle its substrate and aid the efficient elimi-
nation of harmful molecules by reducing the intracellular
drug concentration to levels below DME saturation in the
proximal region, and increase the residence time of its
substrate for metabolism in the distal gastrointestinal tract.
Although demonstrated in vitro [90], some authors have
pointed out that the extent of such synergistic effects
in vivo is minimal [92]. The extent of activity of DMEs and
P-gp are determined by the drug concentration at the site of
the absorption, which in turn is related to solubility (bio-
pharmaceutical classification) [73] and regional stability of
the substrate in the gut lumen. Murakami and Takano
suggested that the biopharmaceutics classification system
(BCS) Class I compounds that are readily water-soluble
and have high permeability will be rapidly absorbed in the
upper part of the small intestine by passive diffusion [73].
Consequently, these compounds can be extensively
metabolized due to higher CYP450 expression in the
proximal small intestine and lower dependence on P-gp
and/or BCRP [29]. However, BCS class II and III, as well
as intravenous compounds with poor solubility and/or
permeability, are likely to be absorbed in the lower parts of
the intestine where metabolism can be substantial if they
are also substrates of P-gp/BCRP [73]. In conclusion,
compounds with high permeability that are typically
absorbed in the upper region of the small intestine can
escape the combined action and potentiation of metabolism
and efflux, while moderate and low-soluble compounds
have an increased potential to be involved in the recycling
action of transporters.
Metabolites formed by CYP450s can be efficiently
transported to either the mucosal or blood side of the
enterocyte by the action of either MDR1, BCRP or the
MRPs. The metabolite of ropivacain was secreted to a
larger extent on the luminal side of the human jejunum
compared with the ileum [93]. Although the transporters
involved were not identified, examples such as this clearly
highlight the need for a greater understanding of the
interplay between enzymes and transporters in the intesti-
nal tract.
5 Preclinical Models for the Prediction of FG
Various preclinical models of the intestine have been
described (see Table 3). If appropriately integrated into
DMPK strategies for optimization of drug absorption,
distribution, metabolism and excretion (ADME) properties,
it may provide more reliable prediction of human first-pass
oral clearance, bioavailability and PK profile. Models
should be considered in terms of their complexity, the
mechanistic understanding they provide, and their clinical
translation, e.g. quantitative prediction of the fraction of
drug escaping metabolism in the human gut wall.
Often there is a trade-off between the different in vitro,
in situ or in vivo models. On the one hand, in vivo models
retain the native architecture of the small intestine and
physiologically relevant expression profiles of DMEs, co-
factors and transporter proteins. They offer integration of
dynamic processes such as the mesenteric blood circulation
and mucous layer coupled with function to study com-
plexities arising from simultaneous metabolism–transporter
interplay [15, 94, 95]. Notable attractions with in situ
techniques are they closely mimic the in vivo situation yet
provide a unique opportunity to study intestinal events in
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isolation, e.g. absence of biliary excretion and enterohep-
atic recirculation; however, this isolation could compro-
mise the interpretability of the results. Furthermore, species
differences in enzymes and transporters (Table 2) can
make them unreliable for human FG prediction. In vitro
models employing human-specific systems lack native
architecture, but, in combination with mathematical mod-
els, hold the promise of robust prediction, provided there is
a correlation between in vitro and human in vivo.
5.1 In Vivo and In Situ Animal Models
Gut-wall metabolism has been studied in several animal
models [96–102]. By varying sites of drug administration
(oral, intraportal and intravenous routes are common but
intraperitoneal is also used) and PK sampling, the available
fractions in liver and intestine can be calculated from
comparison of AUCs under first-order conditions [103–
107]; however, comparison of intravenous and oral AUCs
after sampling at one site is more straightforward and
routinely applied [108–110]. As such, similar issues
described with the indirect approaches are to be expected.
Despite differences in the CYP450 isoforms expressed in
the rat compared with human (see the following para-
graphs), a good correlation [root mean square error
(RMSE) = 0.19] between rat and human FG has been
reported using a set of 11 CYP3A-metabolized compounds
that had both intravenous and oral PK data [111]. Ten of
these 11 compounds studied had human Fa of 0.8 or higher.
As rat is a good model for human oral drug absorption, it
follows that any differences in the intestinal availability
should arise from intestinal efflux or metabolism. For BCS
class I compounds, good solubility ensures sufficient con-
centrations for the saturation of efflux transporters. A high
permeability rate ensures a low residence time within
enterocytes, resulting in a rate of metabolic extraction that
is limited by the rate of drug permeation through the
enterocytes, rather than by the intrinsic ability of the
intestinal DMEs. With permeability-limited intestinal
extraction, any differences in enzyme isoform, abundance
or activity have limited impact on the metabolic extraction,
especially since CYP450s with broad substrate specificity
abound in both human and rat, and their regional distri-
butions are similar in both species. However, for hepatic
extraction, lower hepatic concentrations compared with the
gut lumen implies a greater role for transporters, while
species differences in plasma protein binding and blood
flow rate contribute to varying exposures to uptake and
efflux transporters, as well as to DMEs, heightening the
impact of differences in transporter and enzyme isoform,
abundance and activities on hepatic extraction. This may
explain why the rat is a good model for the prediction of
human FG but is a poor predictor of human oral
bioavailability [112]. A strong correlation was also repor-
ted between cynomolgus monkey and human FG for human
CYP3A [113]. However, the cost and ethical concerns limit
the availability of monkey PK studies. Animal models may
be useful in the prediction of human FG for CYP3A-me-
tabolized compounds, but not much is known about their
utility for other intestinal DMEs.
In situ approaches include the perfused gut loop, single-
pass and recirculating intestinal perfusions, portal vein
cannulations, portacaval shunts and transpositions [114–
121]. These techniques open the possibility of studying
route-dependent intestinal metabolism following systemic
and luminal drug presentation. This has been shown with
acetaminophen, morphine and enalapril [96, 98, 106, 118,
122, 123]. Naturally-occurring tissue structure and physi-
ology are retained, notwithstanding surgical manipulation
and effect of anaesthetics [114, 124, 125]. Minimal inter-
ference of intestinal function and architecture means opti-
mal tissue viability is maintained [106]. A full complement
of endogenous DMEs and transporter proteins are present.
Discrete segments of the small intestine can be evaluated to
assess the impact of regional differences in DMEs or
transporter expression and gut physiology. Intestinal
metabolism can be more rigorously evaluated if drug
concentrations are measured after sampling from mesen-
teric or portal veins [126]. Detailed methodologies are
provided elsewhere [114, 127–130]. In situ models have
several advantages over in vivo models. For instance,
bypassing the stomach means acidic compounds are unli-
kely to precipitate, and therefore dissolution rates do not
confound intestinal drug concentrations and resultant
plasma levels [94]. These models can be exploited to
investigate metabolism–transporter interplay, as exempli-
fied with midazolam, indinavir and UK-343,664 [48, 131,
132]. Various aspects need to be controlled [133], includ-
ing luminal flow rate and thickness of the unstirred water
layer (UWL), which can be rate-limiting for rapidly
absorbed compounds [106]. In spite of their utility, iso-
lating perfused organs from, or within, the laboratory ani-
mals typically requires specialized surgical procedures. As
such, these approaches are arguably more labour-intensive,
time-consuming and costly compared with other in vivo
and in vitro approaches.
Whereas certain processes, such as passive diffusion,
can be relatively well-predicted from animals [94, 106,
134–139], pronounced species differences in expression of
DME isoforms, substrate selectivity and abundance along
the gastrointestinal tract [30, 31, 113, 140–142] implies
that human FG prediction from preclinical species is not
always feasible. The differences in relative protein
expression of individual CYP450 isoforms in rat, dog,
monkey and human small intestines are presented in Fig. 1.
These species differences have led to substantial
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differences in apparent Fa 9 FG as well as FG [30, 143–
145]. Metabolism studies, using drug substrates for human
CYP450s [141, 143, 146] and UGT enzymes [142, 147],
have generally reported poor correlation between human
and animal FG. Certain DMEs appear to be selectively
expressed in human intestines, including UGT1A8,
UGT1A10 and SULT1A3 [140, 148, 149]. To the best of
our knowledge, there is no known animal orthologue of
SULT1A3 or UGT1A10 [147]. Additionally, there are
known species differences for other enzyme classes
expressed in the gut, such as the carboxylesterases [3, 4,
150, 151]. If a drug is shown to be a substrate for one of
these enzymes then predicting human FG using animal data
would be questionable.
Species differences in regional enzymatic profiles exist
within the intestine (Table 2). The regional decrease in
CYP3A in humans, as a function of distance along the
small intestine from the duodenum to the ileum [9, 85], is
similar to the rat small intestine [152–154]. Interestingly, in
the rat intestine Cyp2b1 is highly expressed, whereas the
equivalent isoform in humans (CYP2B6) is not expressed
[9]. Rat Cyp2b1 is present at much higher protein levels in
the upper parts of the intestine, whereas in humans the
equivalent isoform (CYP2D6) is not [154]. The trend in the
regional expression of rat Cyp2c isoforms (such as
Cyp2c6) is opposite to that of Cyp3a, with higher expres-
sion towards the lower bowel [154] (Table 2). In contrast
to being absent in the human small intestine, the extra-
hepatic enzyme Cyp1a1 has been reported by some authors
to be the predominant CYP450 isoform expressed in rat
small intestine, together with Cyp3a [9, 154–156]. The
glucuronidation/sulphation ratio can differ between regions
according to individual species. In rat colon and proximal
jejunum, the ratio was 16 and 23, respectively [157],
showing a clear species difference in conjugation activity
and regional difference compared with humans (see Sect. 3
and van de Kerkhof et al. [90]).
Regional expression of Mdr1b in rat intestine is similar
to regional expression of MDR1 in the human small
intestine and colon [74–76, 78, 158] (Table 2). Contrary to
this, canine intestinal Mdr1 expression is highest in the
jejunum and very low in the lower parts of the ileum and
colon [159]. For the MRP2 transporter, humans are similar
to rat, with high expression in the proximal small intestine
and very low levels in the lower bowel [74, 78, 83]. Abcc3
(Mrp3) is highly expressed in the colon of rats [160], and
mice, at both the mRNA and protein levels [161] (Table 2).
Interestingly, MRP3 (the corresponding transporter gene in
humans) has the highest level of all the efflux proteins
expressed along the intestinal tract [74]. In mouse, the
expression of bcrp is higher in the mid jejunum compared
with the rest of the intestinal tract [162]. A similar cellular
location (basolateral in enterocytes) found in mice, rats and
humans further supports a high degree of conservation for
ABC transporters amongst eukaryotes.
5.2 Knockout and Transgenic Mouse Models
In vivo rodent models with intestinal or hepatic enzyme
gene knockdown or replacement have demonstrated the
impact of intestinal versus hepatic elimination [163–168].
These knockout (KO) and/or genetically modified (GM),
transgenic (TG) mouse models have been established to
create more reliable in vivo systems to study and predict
human response to novel chemical entities (NCEs) [163,
169–173]. For example, the importance of CYP3A meta-
bolism in the intestine and liver has been illustrated with
docetaxel in KO mice lacking all Cyp3a genes [Cyp3a
(-/-)] [174]. When the CYP3A anticancer drug was
administered intravenously to Cyp3a (-/-) mice, a sev-
enfold increase in systemic exposure was observed com-
pared with wild-type. After oral dosing, an 18-fold higher
systemic exposure was reported. Similar findings were
reported for lopinavir and triazolam (CYP3A) [175, 176],
debrisoquine (CYP2D6) [177] and tolbutamide (CYP2C9)
[178]. This highlights the critical role intestinal CYP3A
plays in human first-pass oral clearance and bioavailability.
Unfortunately, compensatory mechanisms arising from
expression of host (murine) DMEs may confound data
interpretation from KO models. For instance, clearance of











































CYP1A2 not shown, 
detected in n=3 
Fig. 1 Small intestine CYP450 pie charts for rat, dog, monkey and
humans. The mean percentage contributions of individual CYP450
enzymes were calculated from total immunoquantified CYP450
protein (dog, monkey, human) or total spectrally determined
CYP450 (rat). Analysis was based on published data: rat [154], dog
[254, 255], monkey [268] and humans [9]. Additionally, CYP4F2
protein was detected (*7 pmol/mg protein) in human small intestine
microsomal fractions [269]. This has been excluded from the human
CYP450 pie chart because the total intestinal CYP450 content has not
been reported, precluding comparison of relative abundances of
individual enzyme isoforms between studies. CYP450 cytochrome
P450
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midazolam was expected to be severely reduced in Cyp3a
KO mice. In spite of this, metabolism was only marginally
altered versus wild-type [179]. The revelation that several
murine Cyp2c isoforms were significantly upregulated in
Cyp3a KO mice, and could catalyze formation of mida-
zolam 10- and 40-hydroxymidazolam, helped rationalize
these results [179]. In contrast, no such effect was seen
with triazolam, apparently a more selective Cyp3a sub-
strate in mouse [176]. These compensatory mechanisms are
likely to be drug- and species-dependent. In vitro studies
characterizing background metabolism may prevent
assessment of drugs susceptible to elevated host DMEs.
Alternatively, exciting development of a viable mouse
model in which all murine CYP450 genes have been
deleted could avoid this issue altogether [180]. Interest-
ingly, TG mice have been generated that are capable of
expressing human CYP3A4 in the intestine and/or the liver
on top of a mouse Cyp3a KO background [174]. As
demonstrated with docetaxel and lopinavir, these human-
ized mice can provide mechanistic insight into the separate
and combined roles of intestinal and hepatic human
CYP3A, and the interplay with transporters such as P-gp
in vivo [163, 175].
5.3 In Vitro and Mathematical Models
‘Bottom-up’ quantitative predictions that use in vitro data
in conjunction with mathematical models describing pro-
cesses within the gastrointestinal tract have been imple-
mented [181–185]. Several of the in vitro assays
highlighted in Table 3 are simplistic in nature, take less
time to complete, and are a fraction of the cost of animal
experiments. This makes them eminently suited for
screening NCEs and designing out presystemic metabolic
liabilities. Models vary in complexity, from simple mem-
brane preparations of individually recombinantly expressed
enzymes [186–190] to subcellular fractions [12, 43, 45, 85,
153, 191–195], intact cells [196–201] to tissue explants.
The latter retain their in vivo tissue architecture, albeit
lacking physiological surroundings. Although relatively
labour-intensive and lower throughput (see Table 3),
working with whole tissue preparations such as precision
cut tissue slices (PCTS) [157, 202–206], Ussing chamber
[43, 69, 90, 93, 207], everted sac [126, 208–212] and iso-
lated tissue perfusions [94, 197, 213–216] brings with it
several advantages. The cell–cell contacts remain intact, all
cell types are present and the DME systems, co-factors and
transporters are available at physiologically relevant con-
centrations that more closely mimic the in vivo situation.
With the isolated perfusion technique, variables such as
temperature, pH, osmolality, blood pressure and flow can
be controlled [217]. Metabolism on both sides of the
intestine (luminal and vascular) can be studied. However,
maintaining tissue viability is the major issue with this
approach [94]. As such, its application is generally limited
to animal tissue, and short-term incubations (approximately
2 h post-excision) impeding assessment of slowly metab-
olized drugs or enzyme induction [43]. This can be cir-
cumvented in situ but is not without complication. Loss of
tissue viability caused by insufficient oxygenation is also
problematic for everted sacs (1–2 h) and Ussing chambers
preparations (2–4 h) [218–220]. Nevertheless, everted sacs
provide a fast and relatively inexpensive model for mea-
suring regional differences in metabolism [106, 126]. The
small volume inside the sacs offers analytical advantages
over the isolated tissue perfusion and Ussing chamber,
which due to sample dilution require sensitive bioanalysis
to detect drug and/or metabolites [119, 126].
The Ussing chamber can be used with animal or human
tissue providing a good model of drug absorption, trans-
porter interactions, as well as metabolism, during passage
across the gastrointestinal membrane [42, 69, 90, 219, 221–
223]. Drug can be added to luminal or serosal sides,
allowing bidirectional transport and metabolism kinetics to
be studied in different sections of the intestine [106].
Detailed mechanistic interpretation from studies such as
these may require additional insight from experimentation
with enzyme inhibitors, radiolabelled drug, or separate
consideration of metabolism and permeability, e.g. using
intestinal microsomes and Caco-2 monolayers. Indeed the
extent of drug extraction in human intestine (Eg) has been
successfully predicted for testosterone, midazolam and
ropivacaine using human in vitro Ussing experiments [69,
93]. PCTS have received growing attention now that
reproducible production of very thin slices (between 250
and 450 lm) is possible. These maintain better viability
[203] and retain a high drug biotransformation capacity
[43]. PCTS are also suitable for studying regional differ-
ences in intestinal metabolism, as well as regulation of
enzymes and transporters involved in drug disposition
[206, 224]. Applicable to all species, investigations have
been reported in mouse [225], rat [157] and human [90].
Additionally, other tissues can be examined, allowing the
extent of metabolism in different organs to be compared
[204]. Potential drawbacks include poor penetration of
highly metabolized drugs into the slices inner cell layers,
lag time in phase II metabolism, and nonspecific binding to
the slices [202, 226].
Intestinal subcellular fractions (S9 homogenates or
microsomes) are one of the more established in vitro
approaches used in drug discovery. More information has
been published on the physiological scalars (Table 4) and
several investigators have explored quantitative prediction
of FG [49, 111, 227–231]. Commercial availability of
animal and human samples, ease of storage and automa-
tion, make them an attractive option in terms of assay
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speed, capacity and cost. The fractions contain multiple
enriched enzymes in their native configuration for assess-
ment of phase I and selective phase II metabolism [45, 113,
195, 231, 232]; however, they do not contain a full com-
plement of DMEs and lack potentially important interac-
tions with uptake and efflux transporters. Incubations
require the addition of expensive co-factors for optimal
DME activity, often at higher nonphysiological concen-
trations. Others have suggested metabolic rates in S9 and
microsomal fractions can be much lower compared with
matrix such as PCTS [43]. This may be attributed to poor
recovery of enzymes through suboptimal preparation pro-
cedures [195]. Presented in Table 5 are 6b-hydroxy
testosterone rat data (normalized to units of pmol/min/mg
rat intestinal protein) including intrinsic clearance (CLint)
from in-house intestinal microsomes prepared under opti-
mal conditions [233, 234]. Interestingly, in-house micro-
somes achieved broadly similar rates compared with PCTS
and biopsies [43, 205, 225], and were much higher than
previous microsomal preparations [212, 235]. This high-
lights progress made with DME extraction procedures,
which, until recently, have limited the scalability of
intestinal microsomes [192, 195]. Given the profound
effect enzyme extraction procedure and incubation condi-
tions can have on enzyme activity, consensus is needed on
best practise before we can expect significant improve-
ments to the accuracy and reproducibility of predictions.
In vitro models allow the function of metabolic enzymes,
transporters and absorption processes to be studied in the gut
wall. However, to apply this data to retrospectively explain,
or prospectively predict, human oral PK ultimately requires
insight into the mechanisms influencing drug behaviour
in vivo [132, 236–238]. As such, several mechanistic
approaches of varying complexity have been described for
in vitro to in vivo extrapolation (IVIVE), some of which are
available commercially, e.g. GastroPlusTM and Simcyp
[17, 92, 132, 238–241]. These mathematical translations
(Fig. 2) can be relatively straightforward and ‘minimal’
models, such as QGut, require only in vitro metabolic CLint
and cell permeability data to estimate FG. Several groups
have reported successful prediction of FG in animals [242,
243] and humans [49, 227, 228, 244, 245] with this
approach. Drugs with high in vivo extractions (FG values
\0.5) were less accurately predicted and may reflect
inability of the QGut model to account for changes in ente-
rocyte drug concentration and therefore saturation of DME
and efflux transporter processes [246]. However, to the
authors’ knowledge, no critical assessment of possible sys-
tematic underprediction of IVIVE similar to that reported for
hepatic metabolism [247–249] is available in the literature.
Improved FG and oral clearance prediction was noted when
the same set of drugs were evaluated using a physiological-
based PK (PBPK) model. This was partly attributed to the
model’s ability to account for saturation of intestinal meta-
bolism by using maximum velocity (Vmax) and Michaelis-
Menten constant Km, the substrate concentration at which
the reaction rate is half of Vmax rather than CLint [246].
Sophisticated PBPK models have been published, such
as the segmental segregated flow model (SSFM), which
encompass all salient variables, e.g. absorption, gastroin-
testinal transit, metabolism, transport and efflux [95, 98].
This allows route-dependent intestinal metabolism and
Table 4 Reported literature values of intestinal protein scalars in rat, dog and human
Scalar Methodology Rat Dog Human References
Intestinal protein (mg/intestine) PCTS 434 – – [204]





970.8a [197, 198, 254, 255, 270]
Scraping – –
S9 protein (mg/intestine) Homogenization 256.0a – 28,476a,b,c [271, 272]
Elution – – –
Scraping – – 17,540c [85, 273]
Microsomal protein (mg/intestine) Homogenization 17.1b – 3155.1a,b [225, 272]
Elution 54.4d, 16.5a 5459
1918
[194, 197, 254, 255]
Scraping 156a, 114a – 2978 [85, 274]
a Assuming a total intestinal wet weight of 6.9 g [204], 307 g [254, 255] and 809 g [85] for rat, dog and human, respectively
b No correction for losses
c Based on summation of cytosolic and microsomal protein
d Extrapolated to total length (not reported)
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zonal distribution of DMEs and transporters to be consid-
ered, as has been exemplified with morphine [98]. This in
turn provides insight into the likely interplay between
luminal transit, metabolism and active transport [250], and
can be used in experimental design and to explore ‘what if’
scenarios [232, 236, 237, 251]. Comprehensive review of
these dynamic, integrated modelling approaches have been
provided elsewhere [238, 240, 252, 253]. Often, disad-
vantages perceived with these models relate to their
inherent complexity and the level of detail required on
parameters used in predictions. For example, transporter
kinetic data (Km and Vmax) are often lacking, and abun-
dance data for individual DMEs and transporters for the
in vitro models and intact tissues are limited and hence
restrictive to IVIVE [16, 246]. In response, proteomic- and
mass spectrometry-based methods for protein quantifica-
tion and establishment of scaling factors have started to
emerge [32, 149, 254–256].
6 Strategy
An integrated DMPK strategy has been proposed to iden-
tify the right compound in the right assay at the right time
[257]. Assessing the oral absorption potential of a candi-
date drug (CD) is a key component to this strategy.
Improvements made to preclinical models of gut-wall
metabolism (Table 3), and quantitative, mechanistic
understanding of processes governing the magnitude of FG
[132, 246, 250], present a compelling rationale for inclu-
sion of a gut-wall metabolism strategy. The strategy out-
lined in Fig. 3 can be implemented along the drug
discovery value chain. Briefly, this would entail profiling
and designing out intestinal metabolic liabilities during
lead identification (LI) and LO phases. If the potential for
gut-wall metabolism still resided in the CD, then detailed
PBPK modelling would be required for scenario setting and
risk assessment. A decision tree to address gut-wall
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8.3b 25 33 0.6 4.2 19.5
Fold change compared
with PCTS
0.04 1.00 1.32 0.02 0.17 0.78
Intersystem factors were used to recalculate the rate of formation data in units of pmol/min/mg intestinal protein (total intestinal protein from
tissue, including muscle) to allow comparison between in vitro methods
CYP cytochrome P450, PCTS precision cut tissue slices, RIM rat intestinal microsomes
a The intersystem factors have been detailed previously [43]
b The intersystem factor was not reported for the everted sac rate data previously published [43]. However, the recalculated value has been
included to facilitate a broader comparison (for the sake of completeness)
c A higher value (39.8 mg protein per gram intestinal wet weight) was determined using an optimized elution method [233]. Taking into account
the same total protein content previously described (121 mg/g wet weight in intestinal tissue), of which 39.8 mg consisted of total epithelial
protein, indicated that 33 % of the intestinal tissue consisted of epithelial cells (intersystem factor 0.33). Of these epithelial cells, 53 % of the
total cellular protein was determined to be microsomal protein (106 enterocytes contained 0.45 mg of total cellular protein, of which 0.24 mg was
microsomal protein: intersystem factor 0.53). With an optimized scraping method, the whole intestinal wall was used, with the exception of the
muscle layers [233]. Accepting that the muscle layer in rat intestine approximated 20 % of the tissue weight [43] gave an intersystem factor of
0.8 9 0.33 = 0.26
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metabolism is provided in Fig. 4. Known structural motifs
(e.g. metabolic handles for direct phase II metabolism or
CYP3A substrates), metabolic instability in relevant
in vitro systems, or intestinal loss indicated in animal
intravenous/oral PK would trigger further evaluation. Signs
of human intestinal metabolic instability would necessitate
risk assessment. The potential magnitude of human FG
would be evaluated in relevant preclinical models
(Table 3) factoring in the compounds physicochemical
properties, biopharmaceutical classification and projected
dose (panel 1, Fig. 4). A workflow (panel 2, Fig. 4) is
proposed for situations whereby significant intestinal loss
limits in vivo exposure in safety or efficacy models. Cir-
cumstances such as these may require additional studies to
identify whether absorption (permeability/solubility),
transporters and/or intestinal metabolism are responsible.
Certain preclinical models may better complement the
strategy and decision tree outlined above. During the LI
and LO phases, scaled animal and human intestinal
microsomal data could provide an efficient means to
benchmark the risk of achieving low human FG, and also
help troubleshoot underlying causes of intestinal loss in
PK species. These data can also be readily incorporated
into PBPK models for quantitative prediction of FG and
simulation of oral PK profiles [258, 259]. Towards CD
nomination, more physiological relevant models such as
the Ussing chamber may be introduced, facilitating esti-
mation of Fa in the context of metabolism/transporter
interplay. Recently, this technique has shown value in
predicting human absorption for drugs that are substrates
for DMEs and/or transporters expressed in the gut wall
[69].
Fig. 2 Bottom-up approach for prediction of FG using established
in vitro systems and mathematical models of the gut. ACAT Advanced
compartmental absorption and transit model [239, 275], ADAM
advanced dissolution absorption metabolism model [92], GITA
gastrointestinal transit absorption model [276, 277], Qgut minimal
static model of intestinal metabolism [227], RAF relative activity
factor, REF relative expression factor, ISEF intersystem extrapolation
factor [190, 201, 227, 278, 279], CLint intrinsic clearance, MPPI
microsomal protein per gram intestine, PI per intestine, S9PPI S9
protein per gram intestine, EG extraction ratio in the gut [69], PCTS
precision cut tissue slices, CLint,G intrinsic clearance per gram
intestine, SIM small intestinal metabolism, TM traditional model,
SFM segregated flow model, SSFM segmental segregated flow model
686 S. A. Peters et al.
Fig. 4 Decision tree for risk assessment of gut-wall metabolism
mediated via CYP450s, carboxylesterases, SULTs and UGTs. Note,
as FH approaches 1 calculation of Fa 9 FG becomes sensitive to the
value used for liver blood flow. Intestinal microsomal CLint is scaled
to a CLint,u,G then transformed using a model such as Qgut to an
estimated FG.
#For CYP3A substrates, physiological scaling factors
accounting for relative CYP3A abundance in human liver microsomes
and hepatocytes can also be applied to estimate CLint,u,G. *The
solubility range required for an acceptable Fa is dependent on dose.
Solubility is frequently reassessed during drug discovery and early
development phases and the FG liability, in the context of Fa, can be
revisited as understanding of an NCEs’ solubility profile is developed.
Initial measurement of thermodynamic solubility, potentially on
amorphous material, would be replaced with solubility of crystalline
material, and then potentially solubility in biorelevant media (e.g.,
simulated intestinal fluids). Additionally, the pKa (ion class-depen-
dent) can be assessed on representative compounds to allow
simulation of Fa using established PBPK models [92, 239, 280–
282]. CYP450 cytochrome P450, UGTs uridine diphospho-glucurono-
syltransferases, SULTs sulphotransferases, CLint intrinsic clearance,
Qgut minimal static model of intestinal metabolism, IV intravenous,
PO oral, PK pharmacokinetics, NCEs novel chemical entities, PBPK
physiological-based pharmacokinetic, Fa Fraction of orally adminis-
tered drug absorbed into enterocytes, FG fraction of drug escaping
first-pass metabolism in the enterocytes, ER efflux ratio, Papp apparent
permeability, Fa 9 FG intestinal availability, FH fraction of drug
escaping first-pass hepatic metabolism and biliary secretion, NCEs
new chemical entities, CLint,G intrinsic clearance per gram intestine
Fig. 3 Strategy to address the impact of gut-wall metabolism on oral bioavailability during drug discovery phases. LI lead identification, LO
lead optimization, CD candidate drug, PK pharmacokinetics
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7 Challenges and Future Perspectives
When two or more drugs are coadministered, the effects
could be additive, synergistic or antagonistic due to DDIs
affecting the absorption and/or therapeutic profile of the
victim drug. Overlapping substrate specificities for multi-
ple enzymes and transporters might also enhance the
complexity of the absorption profile along the gastroin-
testinal tract. Thus, overall understanding is a result of
complex interplay between physiological (e.g. enzymes
and transporters, blood flow, region of the intestine, lumi-
nal fluid composition) and physicochemical factors (e.g.
pKa, solubility, dissolution, lipophilicity, substrate to
enzymes and/or transporters) characterizing the drug
molecule. In addition, genetic polymorphisms in drug
transporter and DMEs, as well as disease states, may be
responsible for variability in the profile and adverse events
arising from co-medication among patients, which may be
different from healthy volunteers [260] and is difficult to
predict from preclinical tools.
In this review, we have illustrated the PK complexity
associated with oral administration of drugs linked to
intestinal regional variation in DMEs/transporters, as well
as species and model differences. Assessing whether clin-
ical candidates have the right risk/benefit balance for
patients can be challenging given the inherent complexities
and difficulties in the early screening phase and translation
into clinical use. Because of the complexity, PBPK mod-
elling will be a crucial tool as it enables efficient integra-
tion of knowledge on compound behaviour with the
dynamics of intestinal physiology in the preclinical models
and humans [236]. However, for successful modelling,
high-quality data from in vitro and in vivo preclinical tools
needs to be generated (see above strategy). New bioana-
lytical tools for quantitatively analyzing DME [149, 255,
261, 262] and transporter [33, 256, 263, 264] isoform
abundances are already available to improve the quantita-
tive translation between preclinical animals and humans,
and will benefit understanding [185, 256, 265]. Knowledge
of the impact of pharmacogenomics and disease on regio-
nal intestinal availability and variability in underlying
mechanisms is scarce. Alongside this, reports focused on
back translation of clinical outcome that enable evaluation
of the successes or failures of predictions, made from
preclinical data, will be crucial to advancing understanding
and selection of the best tools for future development
activities.
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